Literature DB >> 27622029

Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer.

Gautier Stoll1, Kristina Iribarren2, Judith Michels3, Alexandra Leary4, Laurence Zitvogel5, Isabelle Cremer6, Guido Kroemer7.   

Abstract

Loss of expression of calreticulin (CALR) has been detected by immunohistochemistry in a fraction of non-small cell lung cancers (NSCLC) and has been demonstrated to have a major negative prognostic impact on overall patient survival. Here, we analyzed the impact of CALR expression levels detected by microarray finding a positive correlation between CALR and the expression of a metagene indicating the presence of cytotoxic T lymphocytes (CTL) in NSCLC and ovarian cancer. In addition, we detected a positive correlation with a metagene suggestive of activated dendritic cell (aDC) infiltration in ovarian cancer. Combination of two parameters (CALR + DC (dendritic cell) in NSCL and CALR + aDC in ovarian cancer) or three parameters (CALR + CTL + DC in NSCL and CALR + CTL + aDC in ovarian cancer) had a significant impact on overall patient survival in NSCL (Adenoconsortium) and ovarian cancer (TCGA collection), allowing the stratification of patients in high-risk and low-risk groups. In addition, CALR and aDC alone have a significant impact on overall survival in ovarian cancer. In contrast, in mammary, colorectal and prostate cancer, CALR had no impact on patient survival if analyzed alone or in combination with the immune infiltrate. In addition, CALR correlates with CTL infiltrate in three cancer types (colorectal, breast, ovarian). Altogether, these results support the contention that, at least in some cancers, loss of CALR expression may negatively affect immunosurveillance, thereby reducing patient survival.

Entities:  

Keywords:  Calreticulin; colorectal cancer; cytotoxic T lymphocytes; dendritic cell; immunosurveillance; mammary carcinoma; non-small cell lung cancer; ovarian cancer; prostate cancer

Year:  2016        PMID: 27622029      PMCID: PMC5006900          DOI: 10.1080/2162402X.2016.1177692

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  34 in total

1.  Disrupted WNT signaling in mouse embryonic stem cells in the absence of calreticulin.

Authors:  Jody Groenendyk; Marek Michalak
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

2.  Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP.

Authors:  B Sadasivan; P J Lehner; B Ortmann; T Spies; P Cresswell
Journal:  Immunity       Date:  1996-08       Impact factor: 31.745

3.  Calreticulin exposure dictates the immunogenicity of cancer cell death.

Authors:  Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

4.  An immunosurveillance mechanism controls cancer cell ploidy.

Authors:  Laura Senovilla; Ilio Vitale; Isabelle Martins; Maximilien Tailler; Claire Pailleret; Mickaël Michaud; Lorenzo Galluzzi; Sandy Adjemian; Oliver Kepp; Mireia Niso-Santano; Shensi Shen; Guillermo Mariño; Alfredo Criollo; Alice Boilève; Bastien Job; Sylvain Ladoire; François Ghiringhelli; Antonella Sistigu; Takahiro Yamazaki; Santiago Rello-Varona; Clara Locher; Vichnou Poirier-Colame; Monique Talbot; Alexander Valent; Francesco Berardinelli; Antonio Antoccia; Fabiola Ciccosanti; Gian Maria Fimia; Mauro Piacentini; Antonio Fueyo; Nicole L Messina; Ming Li; Christopher J Chan; Verena Sigl; Guillaume Pourcher; Christoph Ruckenstuhl; Didac Carmona-Gutierrez; Vladimir Lazar; Josef M Penninger; Frank Madeo; Carlos López-Otín; Mark J Smyth; Laurence Zitvogel; Maria Castedo; Guido Kroemer
Journal:  Science       Date:  2012-09-28       Impact factor: 47.728

5.  Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte.

Authors:  Shyra J Gardai; Kathleen A McPhillips; S Courtney Frasch; William J Janssen; Anna Starefeldt; Joanne E Murphy-Ullrich; Donna L Bratton; Per-Arne Oldenborg; Marek Michalak; Peter M Henson
Journal:  Cell       Date:  2005-10-21       Impact factor: 41.582

6.  The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.

Authors:  Sylvain Ladoire; David Enot; Laura Senovilla; François Ghiringhelli; Vichnou Poirier-Colame; Kariman Chaba; Michaela Semeraro; Marie Chaix; Frédérique Penault-Llorca; Laurent Arnould; Marie Laure Poillot; Patrick Arveux; Suzette Delaloge; Fabrice Andre; Laurence Zitvogel; Guido Kroemer
Journal:  Autophagy       Date:  2016-03-16       Impact factor: 16.016

Review 7.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Authors:  Jérôme Galon; Helen K Angell; Davide Bedognetti; Francesco M Marincola
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

8.  Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.

Authors:  Jitka Fucikova; Etienne Becht; Kristina Iribarren; Jeremy Goc; Romain Remark; Diane Damotte; Marco Alifano; Priyanka Devi; Jerome Biton; Claire Germain; Audrey Lupo; Wolf Herve Fridman; Marie-Caroline Dieu-Nosjean; Guido Kroemer; Catherine Sautès-Fridman; Isabelle Cremer
Journal:  Cancer Res       Date:  2016-02-03       Impact factor: 12.701

9.  Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies.

Authors:  Gautier Stoll; Gabriela Bindea; Bernhard Mlecnik; Jérôme Galon; Laurence Zitvogel; Guido Kroemer
Journal:  Oncotarget       Date:  2015-05-20

10.  Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set.

Authors:  Abdul Qader Sukkurwala; Sandy Adjemian; Laura Senovilla; Mickaël Michaud; Sabrina Spaggiari; Erika Vacchelli; Elisa Elena Baracco; Lorenzo Galluzzi; Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2014-04-16       Impact factor: 8.110

View more
  25 in total

1.  Metabolic enzymes expressed by cancer cells impact the immune infiltrate.

Authors:  Gautier Stoll; Margerie Kremer; Normal Bloy; Adrien Joseph; Maria Castedo; Guillaume Meurice; Christophe Klein; Lorenzo Galluzzi; Judith Michels; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-03-30       Impact factor: 8.110

2.  Pro-necrotic molecules impact local immunosurveillance in human breast cancer.

Authors:  Gautier Stoll; Yuting Ma; Heng Yang; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2017-04-17       Impact factor: 8.110

Review 3.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

Review 4.  A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers.

Authors:  Oliver Kepp; Allan Sauvat; Marion Leduc; Sabrina Forveille; Peng Liu; Liwei Zhao; Lucillia Bezu; Wei Xie; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-04-26       Impact factor: 8.110

Review 5.  The immune contexture in cancer prognosis and treatment.

Authors:  Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2017-07-25       Impact factor: 66.675

6.  Endoplasmic reticulum stress-mediated membrane expression of CRT/ERp57 induces immunogenic apoptosis in drug-resistant endometrial cancer cells.

Authors:  Qin Xu; Chuanben Chen; An Lin; Yunqing Xie
Journal:  Oncotarget       Date:  2017-05-08

Review 7.  Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development.

Authors:  Barbara Montico; Annunziata Nigro; Vincenzo Casolaro; Jessica Dal Col
Journal:  Int J Mol Sci       Date:  2018-02-16       Impact factor: 5.923

8.  Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia.

Authors:  Xiufen Chen; Dominick Fosco; Douglas E Kline; Justin Kline
Journal:  Oncoimmunology       Date:  2017-01-10       Impact factor: 8.110

9.  Dexamethasone-Mediated Upregulation of Calreticulin Inhibits Primary Human Glioblastoma Dispersal Ex Vivo.

Authors:  Mohan Nair; Juan Romero; Aria Mahtabfar; Ahmed M Meleis; Ramsey A Foty; Siobhan A Corbett
Journal:  Int J Mol Sci       Date:  2018-02-14       Impact factor: 5.923

Review 10.  Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death.

Authors:  Zahra Asadzadeh; Elham Safarzadeh; Sahar Safaei; Ali Baradaran; Ali Mohammadi; Khalil Hajiasgharzadeh; Afshin Derakhshani; Antonella Argentiero; Nicola Silvestris; Behzad Baradaran
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.